Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena:
Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the South Korean biotech to license its recombinant ...
↧